LSR

Across TCGA pan-cancer cohorts, LSR mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LSR data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LSR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LSR expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where LSR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.524	1.000	<.001	35	view →
LUAD	DFS	Quartile	II,III,IV	0.247	0.644	.005	9	view →
PDAC	OS	Median	II,III,IV	0.884	0.778	.041	3	view →
HNSC	DFS	Tertile	III,IV	0.915	1.000	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LSR–CCRCC (DFS)

Open the CCRCC breakdown →